AG˹ٷ

STOCK TITAN

[8-K] Palo Alto Networks, Inc. Reports Material Event

Filing Impact
(Moderate)
Filing Sentiment
(Neutral)
Form Type
8-K
Rhea-AI Filing Summary

CVS Health’s Q2-25 10-Q shows top-line strength but margin pressure. Total revenue rose 8.4% YoY to $98.9 bn on higher pharmacy volumes (+9% Pharmacy & Consumer Wellness) and PBM growth (+10% Health Services). Six-month revenue is up 7.7% to $193.5 bn.

Profitability weakened. Q2 operating income fell 22% to $2.38 bn and net income attributable to CVS dropped 42% to $1.02 bn; diluted EPS slid to $0.80 (vs $1.41). For the first half, EPS declined 3% to $2.21, reflecting cost inflation, $448 mn premium deficiency on individual exchange products (recorded Q1) and an additional $471 mn reserve for Group Medicare Advantage in Q2. The Health Services unit also booked $288 mn of losses tied to exiting ACO REACH and selling its MSSP operations (including a $236 mn loss on divestiture).

Cash & balance sheet. Operating cash flow fell to $6.45 bn (-19% YoY). Cash & equivalents climbed to $11.8 bn (from $8.6 bn) aided by lower CapEx and debt repayments ($0.8 bn repaid; no new long-term debt issued). Net debt fell ~2 %, while equity rose to $77.4 bn. No share buybacks YTD; dividends of $0.665 per share continue.

Management confirms four-segment structure and notes planned exit from ACA individual exchanges by Jan-26. 1.268 bn shares were outstanding at 7/23/25.

Il 10-Q del secondo trimestre 2025 di CVS Health mostra una crescita dei ricavi ma una pressione sui margini. Il fatturato totale è aumentato dell'8,4% su base annua, raggiungendo 98,9 miliardi di dollari, grazie a volumi più elevati in farmacia (+9% Farmacia e Benessere del Consumatore) e alla crescita del PBM (+10% Servizi Sanitari). I ricavi per sei mesi sono cresciuti del 7,7% a 193,5 miliardi di dollari.

La redditività si è indebolita. Il reddito operativo del secondo trimestre è diminuito del 22% a 2,38 miliardi di dollari e l'utile netto attribuibile a CVS è calato del 42% a 1,02 miliardi di dollari; l'EPS diluito è sceso a 0,80 dollari (da 1,41). Nel primo semestre, l'EPS è diminuito del 3% a 2,21 dollari, riflettendo l'inflazione dei costi, una carenza di premio di 448 milioni sui prodotti individuali degli scambi (registrata nel primo trimestre) e una riserva aggiuntiva di 471 milioni per il Medicare Advantage di gruppo nel secondo trimestre. L'unità Servizi Sanitari ha inoltre registrato perdite per 288 milioni legate all'uscita da ACO REACH e alla vendita delle sue operazioni MSSP (compresa una perdita di 236 milioni sulla cessione).

Liquidità e bilancio. Il flusso di cassa operativo è sceso a 6,45 miliardi di dollari (-19% su base annua). La liquidità e gli equivalenti sono aumentati a 11,8 miliardi (da 8,6 miliardi), grazie a una riduzione del CapEx e al rimborso del debito (0,8 miliardi rimborsati; nessun nuovo debito a lungo termine emesso). Il debito netto è diminuito di circa il 2%, mentre il patrimonio netto è salito a 77,4 miliardi. Nessun riacquisto di azioni dall'inizio dell'anno; i dividendi di 0,665 dollari per azione continuano.

La direzione conferma la struttura a quattro segmenti e segnala l'uscita prevista dagli scambi individuali ACA entro gennaio 2026. Al 23 luglio 2025 erano in circolazione 1,268 miliardi di azioni.

El 10-Q del segundo trimestre de 2025 de CVS Health muestra fortaleza en los ingresos pero presión en los márgenes. Los ingresos totales aumentaron un 8,4% interanual hasta 98,9 mil millones de dólares, impulsados por mayores volúmenes en farmacia (+9% Farmacia y Bienestar del Consumidor) y crecimiento en PBM (+10% Servicios de Salud). Los ingresos de seis meses aumentaron un 7,7% hasta 193,5 mil millones de dólares.

La rentabilidad se debilitó. El ingreso operativo del segundo trimestre cayó un 22% a 2,38 mil millones de dólares y el ingreso neto atribuible a CVS bajó un 42% a 1,02 mil millones; las ganancias diluidas por acción (EPS) descendieron a 0,80 dólares (frente a 1,41). En el primer semestre, el EPS disminuyó un 3% a 2,21 dólares, reflejando la inflación de costos, un déficit de prima de 448 millones en productos individuales de intercambio (registrado en el primer trimestre) y una reserva adicional de 471 millones para Medicare Advantage grupal en el segundo trimestre. La unidad de Servicios de Salud también registró pérdidas de 288 millones relacionadas con la salida de ACO REACH y la venta de sus operaciones MSSP (incluida una pérdida de 236 millones por desinversión).

Flujo de caja y balance. El flujo de caja operativo cayó a 6,45 mil millones (-19% interanual). El efectivo y equivalentes aumentaron a 11,8 mil millones (desde 8,6 mil millones), impulsados por una menor CapEx y pagos de deuda (0,8 mil millones pagados; no se emitió nueva deuda a largo plazo). La deuda neta disminuyó aproximadamente un 2%, mientras que el patrimonio aumentó a 77,4 mil millones. No hubo recompras de acciones en lo que va del año; los dividendos de 0,665 dólares por acción continúan.

La dirección confirma la estructura de cuatro segmentos y señala la salida planeada de los intercambios individuales ACA para enero de 2026. Al 23/7/25 había 1,268 mil millones de acciones en circulación.

CVS Health� 2025� 2분기 10-Q 보고서는 매출 성장� 마진 압박� 보여줍니�. � 매출은 전년 대� 8.4% 증가� 989� 달러�, 약국 물량 증가(+9% 약국 � 소비� 웰니�)와 PBM 성장(+10% 건강 서비�)� 힘입었습니다. 6개월 매출은 7.7% 증가� 1,935� 달러입니�.

수익성은 약화되었습니�. 2분기 영업이익은 22% 감소� 23.8� 달러, CVS 귀� 순이익은 42% 감소� 10.2� 달러� 기록했으� 희석 주당순이�(EPS)은 0.80달러� 하락했습니다(이전 1.41달러). 상반� EPS� 비용 인플레이�, 1분기� 기록� 개인 교환 상품� 4.48� 달러 보험� 부�, 2분기� 추가� 설정� 그룹 메디케� 어드밴티지� 4.71� 달러 준비금 반영으로 3% 감소� 2.21달러� 기록했습니다. 건강 서비� 부문은 ACO REACH 종료 � MSSP 사업 매각� 관련해 2.88� 달러 손실(매각 손실 2.36� 달러 포함)� 기록했습니다.

현금 � 재무상태. 영업 현금 흐름은 전년 대� 19% 감소� 64.5� 달러입니�. 현금 � 현금� 자산은 86� 달러에서 118� 달러� 증가했으�, 이는 낮은 자본 지출과 부� 상환(8� 달러 상환, 신규 장기 부� 발행 없음)� 기인합니�. 순부채는 � 2% 감소했고 자본은 774� 달러� 증가했습니다. 올해 들어 자사� 매입은 없었으며, 주당 0.665달러 배당금은 계속 지� 중입니다.

경영진은 4� 사업부 구조� 유지하며 2026� 1월까지 ACA 개인 교환 시장에서 철수� 계획임을 확인했습니다. 2025� 7� 23� 기준 발행 주식 수는 12.68� 주입니다.

Le rapport 10-Q du deuxième trimestre 2025 de CVS Health montre une solidité du chiffre d'affaires mais une pression sur les marges. Le chiffre d'affaires total a augmenté de 8,4 % en glissement annuel pour atteindre 98,9 milliards de dollars, grâce à des volumes pharmaceutiques plus élevés (+9 % Pharmacie et Bien-être du consommateur) et à la croissance du PBM (+10 % Services de santé). Le chiffre d'affaires sur six mois est en hausse de 7,7 % à 193,5 milliards de dollars.

La rentabilité s'est affaiblie. Le résultat opérationnel du deuxième trimestre a chuté de 22 % à 2,38 milliards de dollars et le résultat net attribuable à CVS a baissé de 42 % à 1,02 milliard ; le BPA dilué est passé à 0,80 $ (contre 1,41 $). Sur le premier semestre, le BPA a diminué de 3 % à 2,21 $, reflétant l'inflation des coûts, un déficit de prime de 448 millions sur les produits individuels des échanges (enregistré au T1) et une réserve supplémentaire de 471 millions pour le Medicare Advantage groupe au T2. L'unité Services de santé a également enregistré 288 millions de pertes liées à la sortie d'ACO REACH et à la vente de ses opérations MSSP (dont une perte de 236 millions sur la cession).

Trésorerie et bilan. Les flux de trésorerie opérationnels ont chuté à 6,45 milliards (-19 % en glissement annuel). La trésorerie et les équivalents ont augmenté à 11,8 milliards (contre 8,6 milliards), soutenus par une baisse des dépenses d'investissement et des remboursements de dette (0,8 milliard remboursé ; aucune nouvelle dette à long terme émise). La dette nette a diminué d'environ 2 %, tandis que les capitaux propres ont augmenté à 77,4 milliards. Aucun rachat d'actions depuis le début de l'année ; les dividendes de 0,665 $ par action se poursuivent.

La direction confirme la structure en quatre segments et indique la sortie prévue des échanges individuels ACA d'ici janvier 2026. 1,268 milliard d'actions étaient en circulation au 23/07/25.

Der 10-Q-Bericht von CVS Health für das zweite Quartal 2025 zeigt Umsatzstärke, aber Margendruck. Der Gesamtumsatz stieg im Jahresvergleich um 8,4 % auf 98,9 Mrd. USD, bedingt durch höhere Apothekenvolumina (+9 % Apotheke & Verbraucher Wellness) und Wachstum im PBM-Bereich (+10 % Gesundheitsdienstleistungen). Der Umsatz für sechs Monate stieg um 7,7 % auf 193,5 Mrd. USD.

Die Profitabilität schwächte sich ab. Das operative Ergebnis im zweiten Quartal fiel um 22 % auf 2,38 Mrd. USD, und der auf CVS entfallende Nettogewinn sank um 42 % auf 1,02 Mrd. USD; das verwässerte Ergebnis je Aktie (EPS) sank auf 0,80 USD (vorher 1,41 USD). Für das erste Halbjahr sank das EPS um 3 % auf 2,21 USD, was Kosteninflation, eine Prämienunterdeckung von 448 Mio. USD bei individuellen Austauschprodukten (im ersten Quartal erfasst) und eine zusätzliche Rückstellung von 471 Mio. USD für die Gruppen-Medicare-Advantage im zweiten Quartal widerspiegelt. Die Einheit Gesundheitsdienstleistungen verbuchte außerdem Verluste in Höhe von 288 Mio. USD im Zusammenhang mit dem Ausstieg aus ACO REACH und dem Verkauf ihrer MSSP-Operationen (einschließlich eines Verlusts von 236 Mio. USD aus der Veräußerung).

Barmittel & Bilanz. Der operative Cashflow sank auf 6,45 Mrd. USD (-19 % im Jahresvergleich). Barmittel und Zahlungsmitteläquivalente stiegen auf 11,8 Mrd. USD (von 8,6 Mrd.), unterstützt durch geringere Investitionsausgaben und Schuldenrückzahlungen (0,8 Mrd. USD zurückgezahlt; keine neuen langfristigen Schulden aufgenommen). Die Nettoverschuldung sank um ca. 2 %, während das Eigenkapital auf 77,4 Mrd. USD stieg. Bis dato keine Aktienrückkäufe; Dividenden von 0,665 USD pro Aktie werden fortgesetzt.

Das Management bestätigt die Vier-Segment-Struktur und weist auf den geplanten Ausstieg aus den ACA-Einzelhandelsmärkten bis Januar 2026 hin. Am 23.07.2025 waren 1,268 Mrd. Aktien ausstehend.

Positive
  • None.
Negative
  • None.

Insights

TL;DR � Revenue beat, earnings miss; cost headwinds dominate near term.

Top-line momentum remains intact as CVS leverages scale in retail pharmacy and PBM, but gross margin fell 180 bp and SG&A grew 8% as value-based care assets ramp. Premium deficiency reserves and ACO REACH/MSSP exit shaved roughly $0.45 EPS YTD, implying core earnings closer to flat. Cash build and modest debt pay-down de-risk the balance sheet; lack of buybacks preserves flexibility. Guidance risk persists until Medicare Advantage pricing resets in 2026.

TL;DR � Regulatory shifts are driving reserves and strategic exits.

Large reserves for individual exchange and Group MA books highlight reimbursement pressure and utilisation uptick. CVS’s retreat from ACO REACH and MSSP underscores difficulties scaling risk-based primary care under current CMS models. The 2026 withdrawal from ACA exchanges may cut volatility but reduces growth options. Investors should watch 2025/26 rate notices, Star ratings and integration of Oak Street & Signify for margin recovery.

Il 10-Q del secondo trimestre 2025 di CVS Health mostra una crescita dei ricavi ma una pressione sui margini. Il fatturato totale è aumentato dell'8,4% su base annua, raggiungendo 98,9 miliardi di dollari, grazie a volumi più elevati in farmacia (+9% Farmacia e Benessere del Consumatore) e alla crescita del PBM (+10% Servizi Sanitari). I ricavi per sei mesi sono cresciuti del 7,7% a 193,5 miliardi di dollari.

La redditività si è indebolita. Il reddito operativo del secondo trimestre è diminuito del 22% a 2,38 miliardi di dollari e l'utile netto attribuibile a CVS è calato del 42% a 1,02 miliardi di dollari; l'EPS diluito è sceso a 0,80 dollari (da 1,41). Nel primo semestre, l'EPS è diminuito del 3% a 2,21 dollari, riflettendo l'inflazione dei costi, una carenza di premio di 448 milioni sui prodotti individuali degli scambi (registrata nel primo trimestre) e una riserva aggiuntiva di 471 milioni per il Medicare Advantage di gruppo nel secondo trimestre. L'unità Servizi Sanitari ha inoltre registrato perdite per 288 milioni legate all'uscita da ACO REACH e alla vendita delle sue operazioni MSSP (compresa una perdita di 236 milioni sulla cessione).

Liquidità e bilancio. Il flusso di cassa operativo è sceso a 6,45 miliardi di dollari (-19% su base annua). La liquidità e gli equivalenti sono aumentati a 11,8 miliardi (da 8,6 miliardi), grazie a una riduzione del CapEx e al rimborso del debito (0,8 miliardi rimborsati; nessun nuovo debito a lungo termine emesso). Il debito netto è diminuito di circa il 2%, mentre il patrimonio netto è salito a 77,4 miliardi. Nessun riacquisto di azioni dall'inizio dell'anno; i dividendi di 0,665 dollari per azione continuano.

La direzione conferma la struttura a quattro segmenti e segnala l'uscita prevista dagli scambi individuali ACA entro gennaio 2026. Al 23 luglio 2025 erano in circolazione 1,268 miliardi di azioni.

El 10-Q del segundo trimestre de 2025 de CVS Health muestra fortaleza en los ingresos pero presión en los márgenes. Los ingresos totales aumentaron un 8,4% interanual hasta 98,9 mil millones de dólares, impulsados por mayores volúmenes en farmacia (+9% Farmacia y Bienestar del Consumidor) y crecimiento en PBM (+10% Servicios de Salud). Los ingresos de seis meses aumentaron un 7,7% hasta 193,5 mil millones de dólares.

La rentabilidad se debilitó. El ingreso operativo del segundo trimestre cayó un 22% a 2,38 mil millones de dólares y el ingreso neto atribuible a CVS bajó un 42% a 1,02 mil millones; las ganancias diluidas por acción (EPS) descendieron a 0,80 dólares (frente a 1,41). En el primer semestre, el EPS disminuyó un 3% a 2,21 dólares, reflejando la inflación de costos, un déficit de prima de 448 millones en productos individuales de intercambio (registrado en el primer trimestre) y una reserva adicional de 471 millones para Medicare Advantage grupal en el segundo trimestre. La unidad de Servicios de Salud también registró pérdidas de 288 millones relacionadas con la salida de ACO REACH y la venta de sus operaciones MSSP (incluida una pérdida de 236 millones por desinversión).

Flujo de caja y balance. El flujo de caja operativo cayó a 6,45 mil millones (-19% interanual). El efectivo y equivalentes aumentaron a 11,8 mil millones (desde 8,6 mil millones), impulsados por una menor CapEx y pagos de deuda (0,8 mil millones pagados; no se emitió nueva deuda a largo plazo). La deuda neta disminuyó aproximadamente un 2%, mientras que el patrimonio aumentó a 77,4 mil millones. No hubo recompras de acciones en lo que va del año; los dividendos de 0,665 dólares por acción continúan.

La dirección confirma la estructura de cuatro segmentos y señala la salida planeada de los intercambios individuales ACA para enero de 2026. Al 23/7/25 había 1,268 mil millones de acciones en circulación.

CVS Health� 2025� 2분기 10-Q 보고서는 매출 성장� 마진 압박� 보여줍니�. � 매출은 전년 대� 8.4% 증가� 989� 달러�, 약국 물량 증가(+9% 약국 � 소비� 웰니�)와 PBM 성장(+10% 건강 서비�)� 힘입었습니다. 6개월 매출은 7.7% 증가� 1,935� 달러입니�.

수익성은 약화되었습니�. 2분기 영업이익은 22% 감소� 23.8� 달러, CVS 귀� 순이익은 42% 감소� 10.2� 달러� 기록했으� 희석 주당순이�(EPS)은 0.80달러� 하락했습니다(이전 1.41달러). 상반� EPS� 비용 인플레이�, 1분기� 기록� 개인 교환 상품� 4.48� 달러 보험� 부�, 2분기� 추가� 설정� 그룹 메디케� 어드밴티지� 4.71� 달러 준비금 반영으로 3% 감소� 2.21달러� 기록했습니다. 건강 서비� 부문은 ACO REACH 종료 � MSSP 사업 매각� 관련해 2.88� 달러 손실(매각 손실 2.36� 달러 포함)� 기록했습니다.

현금 � 재무상태. 영업 현금 흐름은 전년 대� 19% 감소� 64.5� 달러입니�. 현금 � 현금� 자산은 86� 달러에서 118� 달러� 증가했으�, 이는 낮은 자본 지출과 부� 상환(8� 달러 상환, 신규 장기 부� 발행 없음)� 기인합니�. 순부채는 � 2% 감소했고 자본은 774� 달러� 증가했습니다. 올해 들어 자사� 매입은 없었으며, 주당 0.665달러 배당금은 계속 지� 중입니다.

경영진은 4� 사업부 구조� 유지하며 2026� 1월까지 ACA 개인 교환 시장에서 철수� 계획임을 확인했습니다. 2025� 7� 23� 기준 발행 주식 수는 12.68� 주입니다.

Le rapport 10-Q du deuxième trimestre 2025 de CVS Health montre une solidité du chiffre d'affaires mais une pression sur les marges. Le chiffre d'affaires total a augmenté de 8,4 % en glissement annuel pour atteindre 98,9 milliards de dollars, grâce à des volumes pharmaceutiques plus élevés (+9 % Pharmacie et Bien-être du consommateur) et à la croissance du PBM (+10 % Services de santé). Le chiffre d'affaires sur six mois est en hausse de 7,7 % à 193,5 milliards de dollars.

La rentabilité s'est affaiblie. Le résultat opérationnel du deuxième trimestre a chuté de 22 % à 2,38 milliards de dollars et le résultat net attribuable à CVS a baissé de 42 % à 1,02 milliard ; le BPA dilué est passé à 0,80 $ (contre 1,41 $). Sur le premier semestre, le BPA a diminué de 3 % à 2,21 $, reflétant l'inflation des coûts, un déficit de prime de 448 millions sur les produits individuels des échanges (enregistré au T1) et une réserve supplémentaire de 471 millions pour le Medicare Advantage groupe au T2. L'unité Services de santé a également enregistré 288 millions de pertes liées à la sortie d'ACO REACH et à la vente de ses opérations MSSP (dont une perte de 236 millions sur la cession).

Trésorerie et bilan. Les flux de trésorerie opérationnels ont chuté à 6,45 milliards (-19 % en glissement annuel). La trésorerie et les équivalents ont augmenté à 11,8 milliards (contre 8,6 milliards), soutenus par une baisse des dépenses d'investissement et des remboursements de dette (0,8 milliard remboursé ; aucune nouvelle dette à long terme émise). La dette nette a diminué d'environ 2 %, tandis que les capitaux propres ont augmenté à 77,4 milliards. Aucun rachat d'actions depuis le début de l'année ; les dividendes de 0,665 $ par action se poursuivent.

La direction confirme la structure en quatre segments et indique la sortie prévue des échanges individuels ACA d'ici janvier 2026. 1,268 milliard d'actions étaient en circulation au 23/07/25.

Der 10-Q-Bericht von CVS Health für das zweite Quartal 2025 zeigt Umsatzstärke, aber Margendruck. Der Gesamtumsatz stieg im Jahresvergleich um 8,4 % auf 98,9 Mrd. USD, bedingt durch höhere Apothekenvolumina (+9 % Apotheke & Verbraucher Wellness) und Wachstum im PBM-Bereich (+10 % Gesundheitsdienstleistungen). Der Umsatz für sechs Monate stieg um 7,7 % auf 193,5 Mrd. USD.

Die Profitabilität schwächte sich ab. Das operative Ergebnis im zweiten Quartal fiel um 22 % auf 2,38 Mrd. USD, und der auf CVS entfallende Nettogewinn sank um 42 % auf 1,02 Mrd. USD; das verwässerte Ergebnis je Aktie (EPS) sank auf 0,80 USD (vorher 1,41 USD). Für das erste Halbjahr sank das EPS um 3 % auf 2,21 USD, was Kosteninflation, eine Prämienunterdeckung von 448 Mio. USD bei individuellen Austauschprodukten (im ersten Quartal erfasst) und eine zusätzliche Rückstellung von 471 Mio. USD für die Gruppen-Medicare-Advantage im zweiten Quartal widerspiegelt. Die Einheit Gesundheitsdienstleistungen verbuchte außerdem Verluste in Höhe von 288 Mio. USD im Zusammenhang mit dem Ausstieg aus ACO REACH und dem Verkauf ihrer MSSP-Operationen (einschließlich eines Verlusts von 236 Mio. USD aus der Veräußerung).

Barmittel & Bilanz. Der operative Cashflow sank auf 6,45 Mrd. USD (-19 % im Jahresvergleich). Barmittel und Zahlungsmitteläquivalente stiegen auf 11,8 Mrd. USD (von 8,6 Mrd.), unterstützt durch geringere Investitionsausgaben und Schuldenrückzahlungen (0,8 Mrd. USD zurückgezahlt; keine neuen langfristigen Schulden aufgenommen). Die Nettoverschuldung sank um ca. 2 %, während das Eigenkapital auf 77,4 Mrd. USD stieg. Bis dato keine Aktienrückkäufe; Dividenden von 0,665 USD pro Aktie werden fortgesetzt.

Das Management bestätigt die Vier-Segment-Struktur und weist auf den geplanten Ausstieg aus den ACA-Einzelhandelsmärkten bis Januar 2026 hin. Am 23.07.2025 waren 1,268 Mrd. Aktien ausstehend.

Palo Alto Networks Inc false 0001327567 0001327567 2025-07-31 2025-07-31
 
 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

 

FORM 8-K

 

 

CURRENT REPORT

Pursuant to Section 13 or 15(d)

of The Securities Exchange Act of 1934

July 31, 2025

Date of Report (Date of earliest event reported)

 

 

PALO ALTO NETWORKS, INC.

(Exact name of registrant as specified in its charter)

 

 

 

Delaware   001-35594   20-2530195
(State or other jurisdiction
of incorporation)
  (Commission
File Number)
  (IRS Employer
Identification No.)

3000 Tannery Way

Santa Clara, California 95054

(Address of principal executive offices)

(408) 753-4000

(Registrant’s telephone number, including area code)

Not applicable

(Former name or former address, if changed since last report)

 

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

 

Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

 

Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

 

Commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

 

Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

 

Title of Each Class

 

Trading
Symbol

 

Name of Each Exchange
on Which Registered

Common stock, $0.0001 par value per share   PANW   The Nasdaq Stock Market LLC

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company 

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.  ☐

 

 
 


Item 1.01

Entry into a Material Definitive Agreement.

Merger Agreement

On July 30, 2025, Palo Alto Networks, Inc., a Delaware corporation (“PANW”), entered into an Agreement and Plan of Merger (the “Merger Agreement”) by and among PANW, Athens Strategies Ltd., a company organized under the laws of the State of Israel and a wholly owned subsidiary of PANW (“Merger Sub”), and CyberArk Software Ltd., a company organized under the laws of the State of Israel (“CyberArk”). Pursuant to the Merger Agreement, and upon the terms and subject to the conditions therein, Merger Sub will merge with and into CyberArk (the “Merger”), with CyberArk continuing as the surviving corporation in the Merger and a wholly owned subsidiary of PANW.

Subject to the terms and conditions of the Merger Agreement, at the effective time of the Merger (the “Effective Time”), each outstanding ordinary share, par value NIS 0.01 per share, of CyberArk (the “CyberArk Shares”) will be converted into the right to receive 2.2005 shares of common stock, par value $0.0001 per share, of PANW (the “PANW Shares”) and $45.00 in cash, without interest (together, the “Merger Consideration”). The cash portion of the Merger Consideration is expected to be financed with cash on hand.

Under the terms of the Merger Agreement, the completion of the Merger is subject to certain customary closing conditions, including, among others: (i) the approval of the Merger Agreement and the Merger by the affirmative vote of the holders of a simple majority of the voting power of CyberArk Shares represented at the CyberArk shareholders meeting and voting thereon (“CyberArk Shareholder Approval”); (ii) the approval for listing on Nasdaq of the PANW Shares to be issued in the Merger; (iii) the effectiveness of a registration statement on Form S-4 filed by PANW registering the PANW Shares to be issued in connection with the Merger; (iv) the accuracy of the parties’ respective representations and warranties in the Merger Agreement, subject to specified materiality qualifications; (v) compliance by the parties with their respective covenants in the Merger Agreement in all material respects; (vi) the absence of any law or order restraining, enjoining, or otherwise prohibiting the consummation of the Merger; (vii) the expiration of the waiting period applicable to the Merger under the Hart-Scott-Rodino Antitrust Improvements Act of 1976, as amended, and receipt of other approvals under specified antitrust and foreign investment laws; (viii) the lapse of at least 50 days after the filing of a merger proposal with the Companies Registrar of the Israeli Corporations Authority and at least 30 days after obtaining CyberArk Shareholder Approval; and (ix) the absence of a material adverse effect (as defined in the Merger Agreement) with respect to each PANW and CyberArk on or after the date of the Merger Agreement that is continuing as of immediately prior to the closing.

The Merger Agreement and the consummation of the transactions contemplated thereby have been unanimously approved by each of the PANW board of directors and the CyberArk board of directors, and the CyberArk board of directors has resolved to recommend to the shareholders of CyberArk to approve the Merger Agreement and the transactions contemplated by the Merger Agreement, including the Merger.

The Merger Agreement contains customary representations, warranties and covenants made by each of PANW, Merger Sub and CyberArk, including, among others, covenants by CyberArk and PANW regarding the conduct of their respective businesses during the pendency of the transactions contemplated by the Merger Agreement, public disclosures and other matters. CyberArk is required, among other things, not to solicit alternative business combination transactions and, subject to certain exceptions, not to engage in discussions or negotiations regarding an alternative business combination transaction.

Both PANW and CyberArk may terminate the Merger Agreement under certain specified circumstances, including, among others, (i) if the Merger is not consummated by July 30, 2026, subject to an extension to October 30, 2026 in order to obtain required regulatory approvals, (ii) if CyberArk Shareholder Approval is not obtained at CyberArk’s shareholders meeting to approve the Merger Agreement, and (iii) if CyberArk materially breaches its covenants not to solicit alternative business combination transactions, CyberArk’s board of directors effects a change of recommendation with respect to the proposed transaction or CyberArk terminates the Merger Agreement to enter into a definitive agreement with respect to a “superior proposal.” In certain circumstances in connection with the termination of the Merger Agreement, including if CyberArk materially breaches its covenants not to solicit alternative business combination transactions, CyberArk’s board of directors effects a change of recommendation, or CyberArk terminates the Merger Agreement to enter into a definitive agreement with respect to a “superior proposal,” CyberArk would be required to pay PANW a termination fee of $750 million in cash. Additionally, if the Merger Agreement is terminated under certain specified circumstances related to the failure to obtain required regulatory approvals, PANW would be required to pay CyberArk a termination fee of $1 billion in cash.


The foregoing description of the Merger Agreement does not purport to be complete and is qualified in its entirety by the full text of the Merger Agreement, a copy of which is filed as Exhibit 2.1 hereto and is incorporated by reference herein. The Merger Agreement has been attached to provide investors with information regarding its terms. It is not intended to provide any other factual information about PANW, Merger Sub or CyberArk. In particular, the assertions embodied in the representations and warranties contained in the Merger Agreement are qualified by information in confidential disclosure letters provided by each of PANW and CyberArk to each other in connection with the signing of the Merger Agreement or in filings of the respective parties with the United States Securities and Exchange Commission (the “SEC”). These confidential disclosure letters contain information that modifies, qualifies and creates exceptions to the representations and warranties and certain covenants set forth in the Merger Agreement. Moreover, the representations and warranties in the Merger Agreement were used for the purposes of allocating risk between PANW and CyberArk rather than establishing matters of fact. Accordingly, the representations and warranties in the Merger Agreement should not be relied on as a characterization of the actual state of facts about PANW, Merger Sub or CyberArk. The Merger Agreement should not be read alone but should instead be read in conjunction with the other information regarding the Merger Agreement, the Merger, PANW, Merger Sub, CyberArk, their respective affiliates and their respective businesses, that will be contained in, or incorporated by reference into, the Registration Statement on Form S-4 that PANW will file, as well as in the Forms 10-K, Forms 10-Q, Forms 8-K and other filings that PANW may make with the SEC and the Forms 20-F and Forms 6-K and other filings that CyberArk may make with the SEC.

 

Item 9.01

Financial Statements and Exhibits.

(d) Exhibits

 

Exhibit
No.

  

Description

2.1*    Agreement and Plan of Merger, dated as of July 30, 2025, by and among Palo Alto Networks, Inc., Athens Strategies Ltd. and CyberArk Software Ltd.
104    The cover page from this Current Report on Form 8-K, formatted in Inline XBRL

 

*

Schedules omitted pursuant to Item 601(b)(2) of Regulation S-K. PANW agrees to furnish supplementally a copy of any omitted schedule to the SEC upon request; provided, however, that PANW may request confidential treatment pursuant to Rule 24b-2 of the Securities Exchange Act of 1934, as amended, for any schedules or exhibits so furnished.


Forward-Looking Statements

This Current Report on Form 8-K relates to a proposed transaction between PANW and CyberArk. This Current Report on Form 8-K includes forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. All statements other than statements of historical or current facts, including, without limitation, statements regarding the benefits of the proposed transaction, statements related to the expected timing of the completion of the proposed transaction, PANW plans, objectives, expectations and intentions, and other statements that are not historical facts, made in this Current Report on Form 8-K are forward-looking. We use words such as “anticipates,” “believes,” “continue,” “estimate,” “expects,” “future,” “intends,” “may,” “plan,” and similar expressions to identify forward-looking statements, although not all forward-looking statements contain these identifying words. Forward-looking statements reflect management’s current expectations and are inherently uncertain. Actual results could differ materially for a variety of reasons.

There are a significant number of factors that could cause actual results to differ materially from forward-looking statements made or implied in this Current Report on Form 8-K, including: the occurrence of any event, change or other circumstance that could give rise to the termination of the proposed transaction between PANW and CyberArk; PANW’s ability to successfully integrate CyberArk’s businesses and technologies; the risk that the expected benefits and synergies of the proposed transaction may not be fully achieved in a timely manner, or at all; the risk that PANW or CyberArk will be unable to retain and hire key personnel; the risk associated with CyberArk’s ability to obtain the approval of its shareholders required to consummate the proposed transaction; the risk that the conditions to the proposed transaction are not satisfied on a timely basis, or at all, or the failure of the proposed transaction to close for any other reason or to close on the anticipated terms; the risk that any regulatory approval, consent or authorization that may be required for the proposed transaction is not obtained or is obtained subject to conditions that are not anticipated or that could adversely affect the expected benefits of the transaction; significant and/or unanticipated difficulties, liabilities or expenditures relating to the transaction; the effect of the announcement, pendency or completion of the proposed transaction on the parties’ business relationships and business operations generally; the effect of the announcement or pendency of the proposed transaction on the parties’ common or ordinary share prices and uncertainty as to the long-term value of PANW’s or CyberArk’s common or ordinary shares; risks related to disruption of management time from ongoing business operations due to the proposed transaction; the outcome of any legal proceedings that may be instituted against PANW, CyberArk or their respective directors; developments and changes in general or worldwide market, geopolitical, economic, and business conditions; failure of PANW’s platformization product offerings; failure to achieve the expected benefits of PANW’s strategic partnerships and acquisitions; changes in the fair value of PANW’s contingent consideration liability associated with acquisitions; risks associated with managing PANW’s growth; risks associated with new product, subscription and support offerings, including product offerings that leverage AI; shifts in priorities or delays in the development or release of new product or subscription or other offerings, or the failure to timely develop and achieve market acceptance of new products and subscriptions as well as existing products, subscriptions and support offerings; failure of PANW’s or CyberArk’s business strategies; rapidly evolving technological developments in the market for security products, subscriptions and support offerings; defects, errors, or vulnerabilities in our products, subscriptions or support offerings; PANW’s customers’ purchasing decisions and the length of sales cycles; PANW’s competition; PANW’s ability to attract and retain new customers; PANW’s ability to acquire and integrate other companies, products, or technologies in a successful manner; PANW’s share repurchase program, which may not be fully consummated or enhance shareholder value, and any share repurchases which could affect the price of its common stock.

For additional risks and uncertainties on these and other factors that could cause actual results to differ materially from those described in the forward-looking statements, please refer to PANW’s and CyberArk’s respective periodic reports and other filings with the SEC, including the risk factors contained in PANW’s and CyberArk’s annual report on Form 10-K or 20-F, as applicable, periodic quarterly reports on Form 10-Q or reports of foreign private issuer on Form 6-K, as applicable. All forward-looking statements in this Current Report on Form 8-K are based on current beliefs and information available to management as of the date hereof, and neither PANW nor CyberArk assumes any obligation to update the forward-looking statements provided to reflect events that occur or circumstances that exist after the date on which they were made.


No Offer or Solicitation

This Current Report on Form 8-K is not intended to and shall not constitute an offer to buy or sell or the solicitation of an offer to buy or sell any securities or a solicitation of any vote or approval, nor shall there be any sale of securities in any jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such jurisdiction. No offering of securities shall be made, except by means of a prospectus meeting the requirements of Section 10 of the U.S. Securities Act of 1933, as amended.

Additional Information about the Merger and Where to Find It

In connection with the proposed transaction, PANW intends to file with the SEC a registration statement on Form S-4, which will include a proxy statement of CyberArk that also constitutes a prospectus of PANW common shares to be offered in the proposed transaction. Each of PANW and CyberArk may also file or furnish other relevant documents with the SEC regarding the proposed transaction. This Current Report on Form 8-K is not a substitute for the proxy statement/prospectus or registration statement or any other document that PANW or CyberArk may file or furnish with the SEC or send to security holders in connection with the proposed transaction. The registration statement will include a definitive proxy statement/prospectus, which will be sent to shareholders of CyberArk seeking their approval of the proposed transaction. INVESTORS AND SECURITY HOLDERS ARE URGED TO READ THE REGISTRATION STATEMENT ON FORM S-4, THE PROXY STATEMENT/PROSPECTUS INCLUDED WITHIN THE REGISTRATION STATEMENT ON FORM S-4 AND ANY OTHER RELEVANT DOCUMENTS THAT MAY BE FILED OR FURNISHED WITH THE SEC, AS WELL AS ANY AMENDMENTS OR SUPPLEMENTS TO THESE DOCUMENTS, CAREFULLY AND IN THEIR ENTIRETY WHEN THEY BECOME AVAILABLE BECAUSE THEY CONTAIN OR WILL CONTAIN IMPORTANT INFORMATION ABOUT THE PROPOSED TRANSACTION. Investors and security holders will be able to obtain free copies of the registration statement and proxy statement/prospectus, when available, and other documents containing important information about PANW, CyberArk and the proposed transaction, once such documents are filed or furnished with the SEC through the website maintained by the SEC at www.sec.gov. Copies of the documents filed with the SEC by PANW will be available free of charge on PANW’s website at www.paloaltonetworks.com or by contacting PANW’s Investor Relations Department by email at [email protected]. Copies of the documents filed or furnished with the SEC by CyberArk will be available free of charge on CyberArk’s website at www.cyberark.com or by contacting CyberArk’s Investor Relations department by email at [email protected] or by phone at 617-558-2132.

 


SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this Current Report on Form 8-K to be signed on its behalf by the undersigned hereunto duly authorized.

 

    PALO ALTO NETWORKS, INC.
Date: July 31, 2025   By:  

/s/ Bruce Byrd

    Name:   Bruce Byrd
    Title:   Executive Vice President and General Counsel
Palo Alto

NASDAQ:PANW

PANW Rankings

PANW Latest News

PANW Latest SEC Filings

PANW Stock Data

122.04B
660.29M
1.05%
81.66%
3.59%
Software - Infrastructure
Computer Peripheral Equipment, Nec
United States
SANTA CLARA